Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Pipetting a DNA (deoxyribonucleic acid) sample into a multiwell plate with DNA information in the background

In the Spotlight

Healthcare & Life Sciences Market Update

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024 Podcast

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Shiny transparent capsule filled with colorful spheres

November 26, 2024 Podcast

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

October 18, 2024 Client Alert

US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2024

Close up of Asian women with hi tech digital technology screen over the eye.

May 30, 2024 Webcast

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

Shot of shelves stocked with various medicinal products in a pharmacy

January 14, 2025 Client Alert

FDA Finalizes Guidance on Communications of Scientific Information on Unapproved Uses

The final guidance describes FDA’s enforcement discretion policy for sharing scientific information on unapproved uses of approved products and suggests a safe harbor for sharing off-label information consistent with the guidance’s recommendations.

January 13, 2025 Resource

Healthcare & Life Sciences Market Update

In this edition, we explore the evolving landscape of investment trends, regulatory challenges, and strategic opportunities shaping the global market.

January 6, 2025 Article

Healthcare and Life Science Deals Attorneys Expect in 2025

December 30, 2024 Podcast

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

December 17, 2024 Podcast

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

May 30, 2024

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

Latham’s healthcare enforcement and antitrust practitioners discuss how companies can navigate the complexities of healthcare consolidation and regulatory compliance. MCLE credit offered.